Acute lymphoblastic leukemia: a comprehensive review and 2017 update

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Acute lymphoblastic leukemia (ALL) is the second most common adult acute leukemia.
• It is characterized by chromosomal abnormalities affecting lymphoid precursor cells.
• Adult ALL predominantly arises from B-cell precursors (75%) or T-cell precursors.

Observation:

• Traditional risk stratification relies on clinical factors like age and WBC count.
• Recurrent genetic alterations are increasingly used to refine prognosis and guide treatment.
• Current standard therapy involves multi-agent chemotherapy and stem cell transplantation.

Findings:

• Despite advances, elderly patients often have poor tolerance and outcomes.
• Recent therapeutic progress is improving management strategies for ALL.
• The review focuses on significant recent developments in ALL treatment.

Implications:

• Advances in ALL treatment are crucial for improving patient survival and quality of life.
• Personalized medicine approaches incorporating genetic data are transforming ALL management.
• Further research is needed to optimize therapies, particularly for vulnerable populations like the elderly.